Literature DB >> 26697449

Lipophilic bisphosphonates plus rapamycin: a deadly combination for KRAS-mutated lung adenocarcinoma.

Wei Liu1, Ting Zhang1, Lixia Guo1, Yanan Yang1.   

Abstract

Entities:  

Year:  2015        PMID： 26697449      PMCID： PMC4671872          DOI： 10.3978/j.issn.2305-5839.2015.09.10

Source DB:  PubMed          Journal:  Ann Transl Med        ISSN： 2305-5839


× No keyword cloud information.
  14 in total

1.  Antroquinonol blocks Ras and Rho signaling via the inhibition of protein isoprenyltransferase activity in cancer cells.

Authors:  Ching-Liang Ho; Jui-Ling Wang; Cheng-Chung Lee; Hsiu-Yi Cheng; Wu-Che Wen; Howard Hao-Yu Cheng; Miles Chih-Ming Chen
Journal:  Biomed Pharmacother       Date:  2014-09-26       Impact factor: 6.529

Review 2.  Autophagy is required for mitochondrial function, lipid metabolism, growth, and fate of KRAS(G12D)-driven lung tumors.

Authors:  Jessie Yanxiang Guo; Eileen White
Journal:  Autophagy       Date:  2013-08-15       Impact factor: 16.016

3.  Repurposing of bisphosphonates for the prevention and therapy of nonsmall cell lung and breast cancer.

Authors:  Agnes Stachnik; Tony Yuen; Jameel Iqbal; Miriam Sgobba; Yogesh Gupta; Ping Lu; Graziana Colaianni; Yaoting Ji; Ling-Ling Zhu; Se-Min Kim; Jianhua Li; Peng Liu; Sudeh Izadmehr; Jaya Sangodkar; Thomas Scherer; Shiraz Mujtaba; Matthew Galsky; Jorge Gomez; Solomon Epstein; Christoph Buettner; Zhuan Bian; Alberta Zallone; Aneel K Aggarwal; Shozeb Haider; Maria I New; Li Sun; Goutham Narla; Mone Zaidi
Journal:  Proc Natl Acad Sci U S A       Date:  2014-12-01       Impact factor: 11.205

4.  A combination therapy for KRAS-driven lung adenocarcinomas using lipophilic bisphosphonates and rapamycin.

Authors:  Yifeng Xia; Yi-Liang Liu; Yonghua Xie; Wei Zhu; Francisco Guerra; Shen Shen; Narayana Yeddula; Wolfgang Fischer; William Low; Xiaoying Zhou; Yonghui Zhang; Eric Oldfield; Inder M Verma
Journal:  Sci Transl Med       Date:  2014-11-19       Impact factor: 17.956

5.  Distinct epidermal growth factor receptor and KRAS mutation patterns in non-small cell lung cancer patients with different tobacco exposure and clinicopathologic features.

Authors:  Issan Yee San Tam; Lap Ping Chung; Wai Sing Suen; Elaine Wang; May C M Wong; Kok Keung Ho; Wah Kit Lam; Shui Wah Chiu; Luc Girard; John D Minna; Adi F Gazdar; Maria P Wong
Journal:  Clin Cancer Res       Date:  2006-03-01       Impact factor: 12.531

Review 6.  Mouse models for lung cancer.

Authors:  Min-chul Kwon; Anton Berns
Journal:  Mol Oncol       Date:  2013-02-19       Impact factor: 6.603

7.  Cancer statistics, 2013.

Authors:  Rebecca Siegel; Deepa Naishadham; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2013-01-17       Impact factor: 508.702

8.  Pooled analysis of the prognostic and predictive effects of KRAS mutation status and KRAS mutation subtype in early-stage resected non-small-cell lung cancer in four trials of adjuvant chemotherapy.

Authors:  Frances A Shepherd; Caroline Domerg; Pierre Hainaut; Pasi A Jänne; Jean-Pierre Pignon; Stephen Graziano; Jean-Yves Douillard; Elizabeth Brambilla; Thierry Le Chevalier; Lesley Seymour; Abderrahmane Bourredjem; Gwénaël Le Teuff; Robert Pirker; Martin Filipits; Rafael Rosell; Robert Kratzke; Bizhan Bandarchi; Xiaoli Ma; Marzia Capelletti; Jean-Charles Soria; Ming-Sound Tsao
Journal:  J Clin Oncol       Date:  2013-04-29       Impact factor: 44.544

Review 9.  Prevalence and natural history of ALK positive non-small-cell lung cancer and the clinical impact of targeted therapy with ALK inhibitors.

Authors:  Puey Ling Chia; Paul Mitchell; Alexander Dobrovic; Thomas John
Journal:  Clin Epidemiol       Date:  2014-11-20       Impact factor: 4.790

Review 10.  Autophagy in cancer.

Authors:  Xiaoyong Zhi; Qing Zhong
Journal:  F1000Prime Rep       Date:  2015-02-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.